Clinical trials: Cisplatin, completed
Esophageal Cancer
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00655876
- Testing
- cetuximab, cisplatin, paclitaxel
- Where
- 175 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Mesothelioma
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003263
- Testing
- recombinant interferon alfa, cisplatin, surgical procedure
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Cis-Platinum Nephropathy, Mannitol Adverse Reaction
The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial
This study include cancer patients who had received chemotherapy that include cisplatin. Patients were randomly assigned to either a mannitol 20 g intravenous single dose after cisplatin or a placebo (saline).
- Trial name
- MACIN (NCT04251689)
- Testing
- Mannitol
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Urothelial Carcinoma
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
The purpose of this study is to see if getting chemotherapy with Gemcitabine and Cisplatin for four 21 day cycles for a total of 12 weeks can help shrink the tumor before undergoing surgery for kidney cancer.
- Trial name
- NCT01261728
- Testing
- Gemcitabine and Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Neutropenia
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
RATIONALE: Colony-stimulating factors may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
- Trial name
- NCT00004192
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Oropharynx Cancer
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy.
- Trial name
- NCT02908477
- Testing
- Adjuvant Radiation Therapy, Docetaxel, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 228 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer, Stage IV Breast Cancer
BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
The purpose of this study is to establish an optimal treatment duration and tolerable cumulative dose for BP-C1 in the treatment of metastatic breast cancer patients who had previously undergone at least three lines of…
- Trial name
- NCT03789019
- Testing
- BP-C1
- Where
- 7 sites in Russia, Thailand
- Volunteers
- 29 people
- Sponsor
- Meabco A/S
Penile Cancer
TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
- Trial name
- NCT06415318
- Testing
- Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Ovarian Neoplasm
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.
- Conditions
- Carcinoma, Ovarian Neoplasm, Endocrine Gland Neoplasm, Urogenital Neoplasms
- Trial name
- NCT03562897
- Testing
- Ocoxin-Viusid
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Gastric Cancer, Histone Deacetylase Inhibitor
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer.
- Trial name
- NCT01045538
- Testing
- Vorinostat, capecitabine, and cisplatin
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Asan Medical Center
Non-Small-Cell Lung Carcinoma
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase II, randomised, controlled, non comparative study with 2 parallel groups: Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of…
- Trial name
- NCT00985855
- Testing
- cisplatin, vinorlebine, cetuximab, cisplatine, etoposide, cetuximab
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Institut de Cancérologie de la Loire
Non-Small-Cell Lung Carcinoma
Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.
The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.
- Trial name
- NCT00191620
- Testing
- Gemcitabine, cisplatin
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Germ Cell Tumor, Testis Cancer
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
This is an open-label, single arm, Phase I dose escalation study in subjects with refractory germ cell tumor (rGCT). This phase I will evaluate the safety and efficacy of SGI-110 in combination with cisplatin in subjects with…
- Conditions
- Germ Cell Tumor, Testis Cancer, Testicular Cancer
- Trial name
- NCT02429466
- Testing
- Guadecitabine (SGI-110)
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Nasser Hanna
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Adenocarcinoma of Colon, Adenocarcinoma of Rectum
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of…
- Conditions
- Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
- Trial name
- NCT01703910
- Testing
- Arm A chemotherapy, arm B chemotherapy
- Where
- 2 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Anal Cancer
Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025090
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 13 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College London (UCL) Cancer Institute
Nasopharyngeal Carcinoma
Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma
Radiotherapy is an important treatment for initial distant metastases nasopharyngeal carcinoma. Total dose and fraction size are important prognostic factors for survival, although to our knowledge the optimal model has not been…
- Trial name
- NCT03598218
- Testing
- Hypofraction radiation, Standard dose IMRT
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints…
- Trial name
- SirTac (NCT02936388)
- Testing
- SIRT, DSM-TACE
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Charite University, Berlin, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.